-

Shareholder Alert: Robbins LLP Announces It Is Investigating Hallmark Financial Services Inc. (HALL) for Misleading Shareholders

SAN DIEGO & DALLAS--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Hallmark Financial Services Inc. (NASDAQ: HALL) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Hallmark Financial underwrites, markets, distributes, and services property/casualty insurance products.

If you suffered a loss as a result of Hallmark Financial's misconduct, click here.

Hallmark Financial Services Inc. (HALL) Dismisses Its Independent Auditor

On March 2, 2020, Hallmark Financial announced that it had exited from the Binding Primary Commercial Auto Business and revealed a $63.8 million loss development for prior underwriting years. Then, on March 11, 2020, the Company disclosed it had dismissed its independent auditor BDO due in large part to a disagreement regarding estimates for reserves on unpaid losses. Finally, on March 17, 2020, Hallmark Financial filed with the SEC a letter from BDO stating BDO had expanded the scope of its audit relating to the disagreement and that "a substantial portion of the requests had not been received and/or tested prior to our termination." Following these disclosures, shares of Hallmark Financial fell from a closing price of $14.33 per share on March 2, 2020 to a closing price of $3.12 per share on March 18, 2020, representing a 78% decline.

If you purchased Hallmark Financial Services Inc. (HALL) securities between March 5, 2019 and March 17, 2020, you have until July 6, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Hallmark Financial settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:HALL

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom